SYNLAB UK & Ireland:

Labco and SYNLAB – Senior Announcements

Published: 1st July 2015

The European clinical diagnostics businesses, Labco and SYNLAB, today announced that Dr. Bartl Wimmer will be appointed as Group Chief Executive and Philippe Charrier as Executive Chairman of the combined group.

This announcement follows the acquisitions of Labco and SYNLAB by European private equity firm Cinven in May and June respectively. These positions will be effective once Cinven’s acquisitions of both Labco and SYNLAB have completed, which is expected to be in September 2015.

Dr. Bartl Wimmer is currently Chief Executive Officer of SYNLAB. He was the co-founder of the SYNLAB business in 1998 and has acted as Managing Director since its establishment. Since January 2010, he has held the position of CEO with responsibility for the successful acquisition and integration of numerous medical diagnostics laboratories across Germany and Europe.

Philippe Charrier is currently Chief Executive Officer of Labco. He joined the Board of Labco in 2011 and was previously CEO of Oenobiol, the personal beauty care product firm. During 1999 to 2006, he was CEO of P&G France. During his tenure as CEO, Philippe Charrier has overseen significant growth and expansion at Labco building it into the pre-eminent operator of clinical laboratories in Western Europe.

I am delighted to be appointed Group CEO of the combined Labco/SYNLAB business. Both these companies are highly successful operators of medical diagnostics laboratories across Europe and have grown strongly in recent years. “The combination of these businesses will enable us to continue developing first class medical diagnostics and allow us to benefit from genuine benefits of scale where we can provide diagnostic services more efficiently to patients and payors. Labco has an excellent team and reputation and I am looking forward to working closely with Philippe Charrier as Executive Chairman.

Dr Bartl Wimmer

The European clinical diagnostics sector is continuing to grow and the combined Labco/SYNLAB Group is extremely well positioned to benefit from the increasing demand for clinical diagnostics services, particularly given the under penetrated and highly fragmented European market. The combined Group will have the strongest medical capabilities in Europe, and will be able to deliver new tests to market to provide improved patient outcomes.

SYNLAB is a highly respected operator within the market and, as Executive Chairman, it will be my role to oversee the gradual combination of the two businesses in a way that harnesses the best of both operations. I am looking forward to working with Bartl Wimmeras Group CEO and believe that together the combined group has an exciting future ahead.

The completion of the Labco and SYNLAB acquisitions remain subject to the satisfaction of customary regulatory approval. These appointments are subject to the completion of the contemplated change of control and the forthcoming integration of these businesses.

Philippe Charrier
Latest SYNLAB UK & Ireland News
SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation

Published: 23rd August 2023 Science for Life, Health and Wellbeing SYNLAB, the medical diagnostics provider, has set out its ambition to become the UK’s leading …

Read More (about 'SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation')
Modern Slavery & Human Trafficking Statement 2023

Published: 11th July 2023 INTRODUCTION This is SYNLAB UK and Ireland’s (SYNLAB UK&I) Modern Slavery and Human Trafficking Statement under Section 54 of the UK…

Read More (about 'Modern Slavery & Human Trafficking Statement 2023')
Exceptional talent honoured during SYNLAB awards programme

Published: 8th December 2022 SYNLAB’s 2022 Excellence Awards recognised individuals and teams from across its UK & Ireland services, who display outstanding service in their…

Read More (about 'Exceptional talent honoured during SYNLAB awards programme')
SYNLAB Primed to Help Steer NHS’s COVID Bounce Back

Published: 13th October 2022 SYNLAB is ready to play a key role in assisting the UK’s ongoing COVID recovery after securing membership of NHS England’s…

Read More (about 'SYNLAB Primed to Help Steer NHS’s COVID Bounce Back')
Landmark Day for Pathology Partnership with Launch of Synnovis Brand

Published: 4th October 2022 A pathology partnership performing 32 million tests a year has been relaunched as ‘Synnovis’ – officially heralding the start of a…

Read More (about 'Landmark Day for Pathology Partnership with Launch of Synnovis Brand')
Pathology laboratory becomes the first in the UK to support remote plate reading  

Published: 15th June 2022 A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB ESG Roadmap and Framework

Published: 17th May 2022 Introduction SYNLAB UK&I is thrilled to publish its UK&I ESG Framework and Roadmap, which outlines out how we will achieve our…

Read More (about 'SYNLAB ESG Roadmap and Framework')
GENDER Pay Gap Report 2020-21

Published: 21st September 2021 A Message From Our CEO Whilst we are pleased at the improvement in our gender pay gap over the past four…

Read More (about 'GENDER Pay Gap Report 2020-21')
SYNLAB Goes Public

Published: 30th April 2021 We are proud to announce that SYNLAB is now listed on the Frankfurt Stock Exchange. This historical milestone is built on…

Read More (about 'SYNLAB Goes Public')